Market Overview

TherapeuticsMD Shares Rally +27% On FBR's Initiation

40 Stocks Moving In Tuesday's Pre-Market Session
40 Biggest Movers From Yesterday

Shares of TherapeuticsMD (NYSE: TXMD) gained 27.6 percent following FBR's initiation. FBR analyst William Tanner initiated coverage on TherapeuticsMD with an Outperform rating and $34.00 price target.

Tanner reported that TherapeuticsMD's TX-001 is likely the only FDA approved bio-identical hormone formulation. The analyst added that the formulation could even change the way women are treated with hormone replacement therapy. FBR emphasized that the company is truly a “big deal” in regards to women's health.

The analyst further noted that TherapeuticsMD may attract a large pharma partner.

Shares of TherapeuticsMD closed at $4.13 on Monday. The stock gained 27.6 percent to $5.27 before seeing some selloff. The stock is currently up 24.4 percent.

Latest Ratings for TXMD

Sep 2017Morgan StanleyInitiates Coverage OnEqual-Weight
Jul 2017Deutsche BankInitiates Coverage OnBuy
Jul 2017OppenheimerUpgradesPerformOutperform

View More Analyst Ratings for TXMD
View the Latest Analyst Ratings

Posted-In: FBRAnalyst Color Health Care Price Target Initiation Hot Analyst Ratings General


Related Articles (TXMD)

View Comments and Join the Discussion!

Partner Center